Assembly Biosciences, Inc (ASMB)

Etorro trading 970x250
Assembly Biosciences, Inc (ASMB) Logo

About Assembly Biosciences, Inc

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California. Address: 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Assembly Biosciences, Inc News and around…

Latest news about Assembly Biosciences, Inc (ASMB) common stock and company :

12 Health Care Stocks Moving In Thursday's After-Market Session
25 Nov, 2021 FinancialContent

Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 17.74% to $3.65 during Thursday's after-market session. The market value of ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
24 Nov, 2021 FinancialContent

Gainers iSpecimen (NASDAQ:ISPC) shares increased by 40.19% to $14.3 during Wednesday's after-market session. At the close, ...

Interesting ASMB Call Options For January 2022
19 Nov, 2021 FinancialContent

Investors in Assembly Biosciences Inc (ASMB) saw new options begin trading this week, for the January 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ASMB options chain for the new January 2022 contracts and identified the following call contract of particular interest.

Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio
12 Nov, 2021 Yahoo! Finance

Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against both pgRNA encapsidation and cccDNA formation ABI-H3733 shows favorable pharmacokinetics and safety in Phase 1a study; Phase 1b study expected to begin in 2022 Vebicorvir Phase 2 open-label study data demonstrate the contribution of core inhibition to deepen viral suppression; Oral presentation scheduled for November 14 at 10 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE N

Analysts See 21% Gains Ahead For IEIH
11 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
04 Nov, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the third quarter ended September 30, 2021. John McHutchison, AO, MD, chief executive officer and president of Assembly Bio, said, “We are excited to advance our latest core inhibitor ABI-4334, with a potential best-in-class p

Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®
01 Nov, 2021 Yahoo! Finance

HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breakingSOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that clinical and preclinical data from its HBV core inhibitor program will be featured in one oral and two poster presentations, including one late breakin

Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection
19 Oct, 2021 Yahoo! Finance

MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial will evaluate ATI-2173, Antios’ investigational proprietary active site polymerase inh

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
06 Oct, 2021 FinancialContent

Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market ...

Assembly Bio Announces October Conference Participation
06 Oct, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), announced participation in the below upcoming conferences focused on HBV: The Science of HBV Cure Meeting 2021 ONLINEPresenter: William Delaney, PhD, Chief Scientific Officer Date/Time: Tuesday, October 12 at 7:30 a.m. ET (7:30 p.m. SGT)Session: Capsid Inhibitors Title: Discovery and

First Week of ASMB May 2022 Options Trading
27 Sep, 2021 FinancialContent

Investors in Assembly Biosciences Inc (ASMB) saw new options become available this week, for the May 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

What Is The Ownership Structure Like For Assembly Biosciences, Inc. (NASDAQ:ASMB)?
24 Sep, 2021 Yahoo! Finance

The big shareholder groups in Assembly Biosciences, Inc. ( NASDAQ:ASMB ) have power over the company. Institutions...

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021
13 Sep, 2021 FinancialContent

Upgrades For Bank of America Corp (NYSE:BAC), Odeon Capital upgraded the previous rating of Hold to Buy. For the second ...

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
03 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

65 Biggest Movers From Yesterday
03 Sep, 2021 FinancialContent

Gainers AgileThought, Inc. (NASDAQ: AGIL) shares surged 69.4% to settle at $23.53 on Thursday. AgileThought 13D Filings from ...

Mid-Afternoon Market Update: Dow Rises 90 Points; Kirkland's Shares Spike Higher
02 Sep, 2021 FinancialContent

Toward the end of trading Thursday, the Dow traded up 0.25% to 35,402.54 while the NASDAQ rose 0.05% to 15,316.38. The S&P also ...

Dow Up Triple Digits, Poised to Snap Three-Day Skid
02 Sep, 2021 FinancialContent

The Dow Jones Industrial Index is staging a bounce off yesterday's lukewarm trading, last seen up 150 points, and set to snap a three-day losing streak.

12 Health Care Stocks Moving In Thursday's Intraday Session
02 Sep, 2021 FinancialContent

Gainers Innate Pharma (NASDAQ:IPHA) shares rose 18.22% to $4.28 during Thursday's regular session. As of 12:30 EST, ...

Mid-Day Market Update: Crude Oil Jumps Over 2%; Assembly Biosciences Shares Plunge
02 Sep, 2021 FinancialContent

Midway through trading Thursday, the Dow traded up 0.42% to 35,461.47 while the NASDAQ rose 0.39% to 15,369.38. The S&P also rose, ...

46 Stocks Moving In Thursday's Mid-Day Session
02 Sep, 2021 FinancialContent

Gainers Sphere 3D Corp. (NASDAQ: ANY) shares surged 36% to $9.02 as traders circulate a tweet from popular Twitter trader Will ...

Mid-Morning Market Update: Markets Open Higher; Hormel Foods Cuts Earnings Outlook
02 Sep, 2021 FinancialContent

Following the market opening Thursday, the Dow traded up 0.18% to 35,377.03 while the NASDAQ rose 0.23% to 15,345.05. The S&P also ...

Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
02 Sep, 2021 FinancialContent

Upgrades For Okta Inc (NASDAQ:OKTA), Needham upgraded the previous rating of Hold to Buy. In the second quarter, Okta ...

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
02 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
02 Sep, 2021 FinancialContent

Gainers Plus Therapeutics (NASDAQ:PSTV) shares increased by 22.1% to $2.32 during Thursday's pre-market session. The ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
02 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time for another eventful day of trading and we're kicking it off with a look at the biggest pre-market stock movers for Thursday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. 8 Tech Stocks to Buy Offering Solid Dividends

28 Stocks Moving in Thursday's Pre-Market Session
02 Sep, 2021 FinancialContent

Gainers Focus Universal Inc. (NASDAQ: FCUV) rose 39.7% to $26.93 in pre-market trading after jumping 278% on Wednesday. Focus ...

Assembly Bio Stock Tumbles On Discontinuation Of Hepatitis B Trial
02 Sep, 2021 FinancialContent

Assembly Biosciences Inc(NASDAQ: ASMB) hasdecided to discontinue the developmentof ABI-H2158 (2158) following the ...

10 Stocks Moving In Wednesday's After-Hours Session
01 Sep, 2021 FinancialContent

Gainers INmune Bio (NASDAQ: INMB) shares are trading higher after the company announced XPro has been found to decrease multiple ...

Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158
01 Sep, 2021 FinancialContent
Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development
18 Aug, 2021 FinancialContent

Assembly Biosciences, Inc (ASMB) is a NASDAQ Common Stock listed in , ,

970x250